Please assess the completion status of the following clinical trial:

Trial Title: ITI-007 (Lumateperone Tosylate) for Schizophrenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) diagnosis of schizophrenia or schizoaffective disorder~* Has capacity to provide informed consent~* Medically stable for study participation~* Judged clinically not to be at significant suicide or violence risk~* Inadequate response or tolerability to previously antipsychotic therapy, as defined by at least one of the following: prior clozapine failure, a PANSS\>80 despite at least six weeks of a current antipsychotic therapy, a Clinical Global Impressions scale-Improvement (CGI-I) of 4 after at least two six week trials of antipsychotics (retrospective assessment) or failure to tolerate an adequate dose of at least antipsychotics (as defined by the Physicians Desk Reference)~Exclusion Criteria:~* Substance abuse within last 90 days~* ECG abnormality that is clinically significant~* Pregnancy, lactation, or lack of use of effective birth control~* Presence or positive history of significant unstable medical or neurological illness (including any history of seizure disorder, hepatitis, renal insufficiency or mental retardation), history of HIV~* Clinically significant abnormal laboratory tests, positive for hepatitis B or C or liver function tests (LFTs) \> 2x Upper Limit of Normal, use of strong CYP3A4 inhibitors or inducers~* History or presence of concomitant major psychiatric illness.~* Use of other antipsychotic medications at baseline.~* Use of another investigational medication in the previous 4 weeks

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- ITI-007 (Type: EXPERIMENTAL): Open-Label ITI-007 40-60 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).